Addressing the Genetics
Workforce Shortage
Susan Capasso, MS, EdD, CGC
Mark Korson, MD
(April 11, 2023)
1
Learning Objectives
By the end of this session, attendees will be able to:
• List some states that are underserved where genetics work is
more likely to fall to PCPs to make up for the gap.
• Describe how PCPs can play a more active role in selected
genetic situations.
• Identify educational opportunities to increase the workforce
in Genetics.
2
Medical Geneticists and
Genetic Counselors
• Medical Geneticist: a physician who has completed
initial primary medical training in another area of
medicine and who subsequently completed at least
two years of additional formal subspecialty training
in clinical genetics.
Medical Geneticists and
Genetic Counselors
• Genetic Counselor: A Master’s degree trained health
care professional who combines a knowledge of basic
science, medical genetics, epidemiological principles,
and counseling theory with skills in genetic risk
assessment, education, interpersonal communication
and counseling to provide services to clients and their
families for a diverse set of genetic or genomic
indications.
Workforce Shortage
Workforce: Geneticists
• ACMG Workforce Survey, 2019
– Genetic counselors = 4700 (7/500,000)
– Medical geneticists = 1240 (2/500,000)
• Number of practicing geneticists?
• Ideal size of a Genetics workforce?
ACMG Survey (2019)
• Age of respondents (n=990)
– Mean = 53 yr +/- 13
– Median = 53 yr (29-91)
• Retirement plans (n=990):
– 5% already retired
– 12% in 1-5 years
– 11% in 6-10 years
• Predicted shortage
– # of respondents > 60 years old
– # who may retire within 10 years
Clinical Geneticist Job Vacancies
0
20
40
60
80
100
120
140
1 2 3 4
#
of
individuals
Number of vacancies
Duration of Vacancies
0
5
10
15
20
25
30
35
40
45
0-2 3-6 7-12 13-24 25-36 37+
#
of
individuals
Length of vacancy (in months)
Medical Geneticists
• Number of
geneticists per
500,000 people
by state
Physician Support Service
• Major regional
medical centers
• No onsite
metabolic
clinician
• 1 onsite
metabolic
clinician
Boston Globe (Oct 17, 2017)
Trainees
• Two-year categorical residencies:
– Programs - 51 (2011)  46 (2017)
– Residents – 80 (2015)  61 (2020)
• Combined residencies:
– Programs – 49 (2011)  80 (2017)
– Residents – 49 (2015) --> 80 (2020)
• Total number of trainees:
– 2014-2015 - 129
– 2019-2020 – 141
Workforce: Genetic Counselors
• Genetic counselors:
• In 2021 the National Society of Genetic
Counselors (NSGC) stated that there was not a
workforce shortage of genetic counselors.
• As of 4/21/21 there were 5,629 certified genetic
counselors (CGC) growing from 1,155 in 1999.
• The profession had grown by 100% since 2010.
Genetic Counseling Workforce
• It is expected in the next 10 years that the
profession will see similar consistent growth
as additional training programs are accredited
and additional training slots are added to
existing programs.
Growth in GC Workforce
Genetic Counseling Workforce
• In 2021 there was over 1 CGC per 75,000
population.
• Excluding nonclinical CGCs, there was about 1
clinical CGC per 100,000 population.
• However, many nonclinical CGCs do have some
interaction with patients, or provide genetics support
to physicians and other healthcare providers.
Access to Genetic Counselors
• In 2021 it was reported that approximately 50% of
clinical CGCs have an appointment available within
a week.
• Close to 90% of CGCs specializing in oncology
reported that they can see a stat patient within 3
days, most on the same day. i
Access to Genetic Counselors
• In some areas of the country or at specific
institutions there are issues in accessing CGCs for
face-to-face appointments.
• However, there are other options to lower wait
times for genetic counseling services such as
telehealth or going to other institutions.
Access to Genetic Counselors
• Pending federal legislation, the Access to Genetic
Counselor Services Act, would provide Medicare
Medicare recognition of CGCs and CMS
reimbursement.
• State licensure can also improve access to genetic
counselor services.
Genetic Roles for the PCP
Cancer Genetics
• Today, genetic testing is becoming more accessible
for patients as the list of clinical indications and
number of genes are growing, and the cost of testing
is decreasing.
• There are many healthcare providers who participate
in the delivery of cancer risk assessment and testing.
PCPs
• The importance of identifying a patient with an
underlying genetic variant associated with cancer is
that it can impact his or her treatment options, long-
term management approach, and risks for other forms
of cancer.
• In addition, there are implications for close family
members.
• Many patients expect PCPs to play a role in risk
identification and genetics referral.
• The potential PCP role in cancer genetics is quite
broad.
Genetic Red Flags
Family history of multiple affected relatives
Condition in the less often affected sex
Earlier age at onset of disease than expected
Disease in the absence of known risk factors
Multiple primary tumors in the same person
Bilateral disease
Non-cancer findings suggestive of a syndrome
Ethnic predisposition
Consanguinity
Autosomal Dominant
Lynch syndrome
• Also known as hereditary non-polyposis colorectal cancer
(HNPCC)
• Most common cause of hereditary colorectal cancer.
• Due to genes that affect DNA mismatch repair, a process that
fixes mistakes made when DNA is copied.
• These genes (MLH1, MSH2, MSH6, PMS2, and EPCAM)
normally protect you from getting certain cancers, but some
mutations in these genes prevent them from working properly.
Lynch syndrome
• More likely to get colorectal cancer and other cancers,
and at a younger age (before 50), including
• Uterine (endometrial),
• Stomach,
• Liver,
• Kidney,
• Brain, and
• Certain types of skin cancers.
• Lynch syndrome causes about 4,200 colorectal cancers
and 1,800 uterine (endometrial) cancers per year.
Results
• Positive for a pathogenic variant
• Negative for a pathogenic variant
• Presence of a variant of uncertain significance
Variant of
Uncertain
Significance
(VUS)
Seen in affected and not affected
These are single nucleotide DNA
polymorphisms that are neither
confirmed benign nor pathogenic
Rates are going down and there
are ACMG guidelines and lab data
available
VUSs
• More are found in individuals
with non-European ancestry who
have been historically
underrepresented in genomic
research.
• The classification of a variant
– benign, uncertain, or
pathogenic – can change over
time as labs generate more data
about specific variants.
• In some cases, a VUS may be
reclassified as "actionable" as
new data is obtained.
Newborn Screening
Propionic acidemia
Methylmalonic acidemia (mutase)
MMA (cobalamin defects)
Isovaleric acidemia
3-MCC deficiency
HMG CoA lyase deficiency
Biotinidase deficiency
Holocarboxylase synthetase def’y
β-ketothiolase deficiency
Glutaric acidemia type I
PKU
Maple syrup urine disease
Homocystinuria
Tyrosinemia type I
Argininosuccinic aciduria
Citrullinemia type I
Guanidinoacetate
methyltransferase def’y
Carnitine update defect
MCAD deficiency
VLCAD deficiency
LCHAD deficiency
TFP deficiency
Galactosemia
Congenital hypothyroidism Critical congenital cyanotic heart disease
Congenital adrenal hyperplasia Cystic fibrosis
Hemoglobinopathies Spinal muscular atrophy
Severe combined immunodeficiency Hearing loss
Other disorders
AMINOACIDOPATHIES ORGANIC ACIDEMIAS FATTY ACID OXIDATION DEFECTS
GALACTOSE DISORDERS
OTHER METABOLIC DISORDERS
RUSP – Core Conditions
Pompe disease
Mucopolysaccharidosis type I
Mucopolysaccharidosis type II
X-linked adrenoleukodystrophy
Methylmalonic acidemia with
homocystinuria
Malonic acidemia
Isobutyrylglycinemia
2-methylbutyrylglycinemia
3-methylglutaconic aciduria
2-methyl-3-OH-butyric aciduria
Arginase deficiency
Citrullinemia type II
Hypermethioninemia
Benign hyperphen
Biopterin
--Synthesis defects
--Regeneration defects
Tyrosinemia II
Tyrosinemia III
SCAD deficiency
LCHAD/MCHAD deficiency
MAD deficiency (GA II)
MCKAT deficiency
2,4-Dienoyl CoA reductase def’
CPT I deficiency
CPT II deficiency
CACT deficiency
Galactokinase def’y
Galactoepimerase
deficiency
Other hemoglobinopathies
T cell-related lymphocyte deficiencies
Other disorders
AMINOACIDOPATHIES ORGANIC ACIDEMIAS FATTY ACID OXIDATION DEFECTS
GALACTOSE DISORDERS
OTHER METABOLIC DISORDERS
RUSP – Secondary Conditions
35
DC
48
55
60
50
60
55
47
33
49
63
31 48
52
57
32 51
37
30
54
44
32
34
60 47 32
55
55
42
31
37
59
47
53
50
66
39
57
60
46
53
58
49
39
36 52
65
62
31
62
50
57
Newborn screening – USA
(disorders/groups of disorders)
Data from Baby’s First test – www.babysfirsttest.org
35
DC
48
55
60
50
60
55
47
33
49
63
31 48
52
57
32 51
37
30
54
44
32
34
60 47 32
55
55
42
31
37
59
47
53
50
66
39
57
60
46
53
58
49
39
36 52
65
62
31
62
50
57
Newborn screening – USA
(disorders/groups of disorders)
Estimated patients diagnosed
with 25 IEMs on RUSP, 2015-2017
~1455/year
(CDC MMWR 2020;69(36):1265-8)
Data from Baby’s First test – www.babysfirsttest.org
Medical Geneticists
• Number of
geneticists per
500,000 people
by state
35
DC
48
55
60
50
60
55
47
33
49
63
31 48
52
57
32 51
37
30
54
44
32
34
60 47 32
55
55
42
31
37
59
47
53
50
66
39
57
60
46
53
58
49
39
36 52
65
62
31
62
50
57
Newborn screening – USA
(disorders/groups of disorders)
Data from Baby’s First test – www.babysfirsttest.org
35
DC
48
55
60
50
60
55
47
33
49
63
31 48
52
57
32 51
37
30
54
44
32
34
60 47 32
55
55
42
31
37
59
47
53
50
66
39
57
60
46
53
58
49
39
36 52
65
62
31
62
50
57
Newborn screening – USA
(disorders/groups of disorders)
Data from Baby’s First test – www.babysfirsttest.org
Abnormal NBS Protocol
• NBS Lab alerts the PCP office
– Repeat specimen
– Referral to a specialist
• PCP office:
– Contacts the family
– Facilitates the referral
– Interacts with the specialist – roles determined
– Supports the family
Abnormal NBS Protocol
• NBS Lab alerts the PCP office
– Repeat specimen
– Referral to a specialist
• PCP office:
– Contacts the family
– Facilitates the referral
– Interacts with the specialist – roles determined
– Supports the family
• Triages the patient
• Initiates testing
• Initiates counseling
Abnormal NBS Protocol
• NBS Lab alerts the PCP office
– Repeat specimen
– Referral to a specialist
• PCP office:
– Contacts the family
– Facilitates the referral
– Interacts with the specialist – roles determined
– Supports the family
• Triages the patient
• Initiates testing
• Initiates counseling
• WITH THE SUPPORT OF A
SKILLED CO-PROVIDER
Triage
• Counseling for abnormal newborn screens
should always be done ASAP
• Management can be:
– Emergent
– Urgent
– Not urgent
Propionic acidemia
Methylmalonic acidemia (mutase)
MMA (cobalamin defects)
Isovaleric acidemia
3-MCC deficiency
HMG CoA lyase deficiency
Biotinidase deficiency
Holocarboxylase synthetase def’y
β-ketothiolase deficiency
Glutaric acidemia type I
PKU
Maple syrup urine disease
Homocystinuria
Tyrosinemia type I
Argininosuccinic aciduria
Citrullinemia type I
Guanidinoacetate
methyltransferase def’y
Carnitine update defect
MCAD deficiency
VLCAD deficiency
LCHAD deficiency
TFP deficiency
Pompe disease
Mucopolysaccharidosis type I
Mucopolysaccharidosis type II
X-linked adrenoleukodystrophy
Galactosemia
Congenital hypothyroidism Critical congenital cyanotic heart disease
Congenital adrenal hyperplasia Cystic fibrosis
Hemoglobinopathies Spinal muscular atrophy
Severe combined immunodeficiency Hearing loss
Other disorders
AMINOACIDOPATHIES ORGANIC ACIDEMIAS FATTY ACID OXIDATION DEFECTS
GALACTOSE DISORDERS
OTHER METABOLIC DISORDERS
Triage – Emergent vs Urgent/Non-urgent
Propionic acidemia
Methylmalonic acidemia (mutase)
MMA (cobalamin defects)
Isovaleric acidemia
3-MCC deficiency
HMG CoA lyase deficiency
Biotinidase deficiency
Holocarboxylase synthetase def’y
β-ketothiolase deficiency
Glutaric acidemia type I
PKU
Maple syrup urine disease
Homocystinuria
Tyrosinemia type I
Argininosuccinic aciduria
Citrullinemia type I
Guanidinoacetate
methyltransferase def’y
Carnitine update defect
MCAD deficiency
VLCAD deficiency
LCHAD deficiency
TFP deficiency
Pompe disease
Mucopolysaccharidosis type I
Mucopolysaccharidosis type II
X-linked adrenoleukodystrophy
Galactosemia
Congenital hypothyroidism Critical congenital cyanotic heart disease
Congenital adrenal hyperplasia Cystic fibrosis
Hemoglobinopathies Spinal muscular atrophy
Severe combined immunodeficiency Hearing loss
Other disorders
AMINOACIDOPATHIES ORGANIC ACIDEMIAS FATTY ACID OXIDATION DEFECTS
GALACTOSE DISORDERS
OTHER METABOLIC DISORDERS
Triage – Emergent vs Urgent/Non-urgent
© Copyright 2017 Mark Korson, MD. All rights reserved
ACMG.net
© Copyright 2017 Mark Korson, MD. All rights reserved
ACMG.net
© Copyright 2017 Mark Korson, MD. All rights reserved
© Copyright 2017 Mark Korson, MD. All rights reserved
ACMG.net
© Copyright 2017 Mark Korson, MD. All rights reserved
ACMG.net
ACMG.net
An Understanding…
• All emergent disease concerns  referral to a
specialist
• All non-emergent diseases with unusual
concerns  referral to a specialist
• A team of skilled co-providers (genetic
counselors?) - thoroughly trained and available
for PCP assistance and guidance
Educational Opportunities
and Resources
Educational Opportunities
• Geneticists:
– Two-years of training
– Combined training with other specialty training
– Possibility in the future of loan repayment
programs for Genetics and/or Metabolism
Educational Opportunities
• To become a genetic counselor, you must first
– earn a minimum of a bachelor's degree: often in the
sciences, such as biology, chemistry, molecular biology in
psychology or sociology.
• Degree Required: Master’s degree Genetic Counseling average
of 21 months, study genetics, psychology, counseling and
sociology
• Certification: Certified Genetic Counselor (CGC) designation
by ABGC after passing the board exam which is offered two
times a year.
• Job Growth (2014-2024): 29%*
• Licensure: Many states including Connecticut and
Massachusetts have licensure
Employment in Clinical Settings
• Prenatal and pre-conception – for women and their partners who are
pregnant or thinking about becoming pregnant
• Pediatric – for children with genetic, or suspected genetic, conditions and
their family members
• Cancer – for patients with cancer and/or their family members
• Cardiovascular – for patients with diseases of the heart or circulatory
system and/or their family members
• Neurology – for patients with diseases of the brain and nervous system
and/or their family members
• Assisted reproductive technology / infertility – for couples struggling with
fertility or who are carriers of genetic diseases
• Psychiatric – for patients living with mental illness and/or their family
members
Employment in Non-clinical Settings
• Research, education, public health settings, and corporate environments.
• Examples of roles include:
Laboratory – Utilization management, provider and patient support,
variant classification, and reporting
Research – Coordinating research studies, patient recruitment, data
collection and interpretation, manuscript preparation and grant writing
Education – Professors, directors of genetic counseling training programs
Public health – Newborn screening programs, population screening
programs
• Non-profit – Patient support and advocacy organizations
• Corporate – Dedicated services for employees and their families
Resources and References
• To learn more about genetics/genetic disorders,
check out:
• New England Regional Genetics Network
(www.negenetics.org)
• Weitzman Institute/NERGN collaboration
(https://www.weitzmaninstitute.org/genetics/)
• www.nsgc.org/Policy-Research-and-Publications/Genetic-Counselor-Workforce
• American College of Obstetricians and Gynecologists (2019) Committee Opinion
#793: Hereditary Cancer Syndromes and Risk Assessment
• Jackson Laboratories Hereditary Cancer Modules
• The primary care physician role in cancer genetics: a qualitative study of patient
experience Fiona A Miller, June C Carroll, Brenda J Wilson, Jessica P
Bytautas, Judith Allanson, Mario Cappelli, Sonya de Laat, Fred Saibil
• Family Practice, Volume 27, Issue 5, October 2010, Pages 563–
569, https://doi.org/10.1093/fampra/cmq035
61
Resources and References
Question #1
There is a shortage of medical geneticists?
A. True
B. False
Question #1
There is a shortage of medical geneticists?
A. True
B. False
Question #2
There is a shortage of genetic counselors?
A. True
B. False
Question #2
There is a shortage of genetic counselors?
A. True
B. False
Question #3
A positive newborn screen for a possible urea
cycle disorder requires an emergent referral to a
specialist.
A. True
B. False
Question #3
A positive newborn screen for a possible urea
cycle disorder requires an emergent referral to a
specialist.
A. True
B. False
Question #4
A positive newborn screen for possible x-linked
adrenoleukodystrophy requires an emergent
referral to a specialist.
A. True
B. False
Question #4
A positive newborn screen for possible x-linked
adrenoleukodystrophy requires an emergent
referral to a specialist.
A. True
B. False
Question #5
A variant of uncertain significance is a
pathogenic variant.
A. True
B. False
Question #5
A variant of uncertain significance is a
pathogenic variant.
A. True
B. False

Addressing Genetics Workforce Shortage - April 11, 2023

  • 1.
    Addressing the Genetics WorkforceShortage Susan Capasso, MS, EdD, CGC Mark Korson, MD (April 11, 2023) 1
  • 2.
    Learning Objectives By theend of this session, attendees will be able to: • List some states that are underserved where genetics work is more likely to fall to PCPs to make up for the gap. • Describe how PCPs can play a more active role in selected genetic situations. • Identify educational opportunities to increase the workforce in Genetics. 2
  • 3.
    Medical Geneticists and GeneticCounselors • Medical Geneticist: a physician who has completed initial primary medical training in another area of medicine and who subsequently completed at least two years of additional formal subspecialty training in clinical genetics.
  • 4.
    Medical Geneticists and GeneticCounselors • Genetic Counselor: A Master’s degree trained health care professional who combines a knowledge of basic science, medical genetics, epidemiological principles, and counseling theory with skills in genetic risk assessment, education, interpersonal communication and counseling to provide services to clients and their families for a diverse set of genetic or genomic indications.
  • 5.
  • 6.
    Workforce: Geneticists • ACMGWorkforce Survey, 2019 – Genetic counselors = 4700 (7/500,000) – Medical geneticists = 1240 (2/500,000) • Number of practicing geneticists? • Ideal size of a Genetics workforce?
  • 7.
    ACMG Survey (2019) •Age of respondents (n=990) – Mean = 53 yr +/- 13 – Median = 53 yr (29-91) • Retirement plans (n=990): – 5% already retired – 12% in 1-5 years – 11% in 6-10 years • Predicted shortage – # of respondents > 60 years old – # who may retire within 10 years
  • 8.
    Clinical Geneticist JobVacancies 0 20 40 60 80 100 120 140 1 2 3 4 # of individuals Number of vacancies
  • 9.
    Duration of Vacancies 0 5 10 15 20 25 30 35 40 45 0-23-6 7-12 13-24 25-36 37+ # of individuals Length of vacancy (in months)
  • 10.
    Medical Geneticists • Numberof geneticists per 500,000 people by state
  • 11.
    Physician Support Service •Major regional medical centers • No onsite metabolic clinician • 1 onsite metabolic clinician
  • 12.
  • 13.
    Trainees • Two-year categoricalresidencies: – Programs - 51 (2011)  46 (2017) – Residents – 80 (2015)  61 (2020) • Combined residencies: – Programs – 49 (2011)  80 (2017) – Residents – 49 (2015) --> 80 (2020) • Total number of trainees: – 2014-2015 - 129 – 2019-2020 – 141
  • 14.
    Workforce: Genetic Counselors •Genetic counselors: • In 2021 the National Society of Genetic Counselors (NSGC) stated that there was not a workforce shortage of genetic counselors. • As of 4/21/21 there were 5,629 certified genetic counselors (CGC) growing from 1,155 in 1999. • The profession had grown by 100% since 2010.
  • 15.
    Genetic Counseling Workforce •It is expected in the next 10 years that the profession will see similar consistent growth as additional training programs are accredited and additional training slots are added to existing programs.
  • 16.
    Growth in GCWorkforce
  • 17.
    Genetic Counseling Workforce •In 2021 there was over 1 CGC per 75,000 population. • Excluding nonclinical CGCs, there was about 1 clinical CGC per 100,000 population. • However, many nonclinical CGCs do have some interaction with patients, or provide genetics support to physicians and other healthcare providers.
  • 18.
    Access to GeneticCounselors • In 2021 it was reported that approximately 50% of clinical CGCs have an appointment available within a week. • Close to 90% of CGCs specializing in oncology reported that they can see a stat patient within 3 days, most on the same day. i
  • 19.
    Access to GeneticCounselors • In some areas of the country or at specific institutions there are issues in accessing CGCs for face-to-face appointments. • However, there are other options to lower wait times for genetic counseling services such as telehealth or going to other institutions.
  • 20.
    Access to GeneticCounselors • Pending federal legislation, the Access to Genetic Counselor Services Act, would provide Medicare Medicare recognition of CGCs and CMS reimbursement. • State licensure can also improve access to genetic counselor services.
  • 21.
  • 22.
    Cancer Genetics • Today,genetic testing is becoming more accessible for patients as the list of clinical indications and number of genes are growing, and the cost of testing is decreasing. • There are many healthcare providers who participate in the delivery of cancer risk assessment and testing.
  • 23.
    PCPs • The importanceof identifying a patient with an underlying genetic variant associated with cancer is that it can impact his or her treatment options, long- term management approach, and risks for other forms of cancer. • In addition, there are implications for close family members. • Many patients expect PCPs to play a role in risk identification and genetics referral. • The potential PCP role in cancer genetics is quite broad.
  • 24.
    Genetic Red Flags Familyhistory of multiple affected relatives Condition in the less often affected sex Earlier age at onset of disease than expected Disease in the absence of known risk factors Multiple primary tumors in the same person Bilateral disease Non-cancer findings suggestive of a syndrome Ethnic predisposition Consanguinity
  • 25.
  • 26.
    Lynch syndrome • Alsoknown as hereditary non-polyposis colorectal cancer (HNPCC) • Most common cause of hereditary colorectal cancer. • Due to genes that affect DNA mismatch repair, a process that fixes mistakes made when DNA is copied. • These genes (MLH1, MSH2, MSH6, PMS2, and EPCAM) normally protect you from getting certain cancers, but some mutations in these genes prevent them from working properly.
  • 27.
    Lynch syndrome • Morelikely to get colorectal cancer and other cancers, and at a younger age (before 50), including • Uterine (endometrial), • Stomach, • Liver, • Kidney, • Brain, and • Certain types of skin cancers. • Lynch syndrome causes about 4,200 colorectal cancers and 1,800 uterine (endometrial) cancers per year.
  • 29.
    Results • Positive fora pathogenic variant • Negative for a pathogenic variant • Presence of a variant of uncertain significance
  • 30.
    Variant of Uncertain Significance (VUS) Seen inaffected and not affected These are single nucleotide DNA polymorphisms that are neither confirmed benign nor pathogenic Rates are going down and there are ACMG guidelines and lab data available
  • 31.
    VUSs • More arefound in individuals with non-European ancestry who have been historically underrepresented in genomic research. • The classification of a variant – benign, uncertain, or pathogenic – can change over time as labs generate more data about specific variants. • In some cases, a VUS may be reclassified as "actionable" as new data is obtained.
  • 32.
  • 33.
    Propionic acidemia Methylmalonic acidemia(mutase) MMA (cobalamin defects) Isovaleric acidemia 3-MCC deficiency HMG CoA lyase deficiency Biotinidase deficiency Holocarboxylase synthetase def’y β-ketothiolase deficiency Glutaric acidemia type I PKU Maple syrup urine disease Homocystinuria Tyrosinemia type I Argininosuccinic aciduria Citrullinemia type I Guanidinoacetate methyltransferase def’y Carnitine update defect MCAD deficiency VLCAD deficiency LCHAD deficiency TFP deficiency Galactosemia Congenital hypothyroidism Critical congenital cyanotic heart disease Congenital adrenal hyperplasia Cystic fibrosis Hemoglobinopathies Spinal muscular atrophy Severe combined immunodeficiency Hearing loss Other disorders AMINOACIDOPATHIES ORGANIC ACIDEMIAS FATTY ACID OXIDATION DEFECTS GALACTOSE DISORDERS OTHER METABOLIC DISORDERS RUSP – Core Conditions Pompe disease Mucopolysaccharidosis type I Mucopolysaccharidosis type II X-linked adrenoleukodystrophy
  • 34.
    Methylmalonic acidemia with homocystinuria Malonicacidemia Isobutyrylglycinemia 2-methylbutyrylglycinemia 3-methylglutaconic aciduria 2-methyl-3-OH-butyric aciduria Arginase deficiency Citrullinemia type II Hypermethioninemia Benign hyperphen Biopterin --Synthesis defects --Regeneration defects Tyrosinemia II Tyrosinemia III SCAD deficiency LCHAD/MCHAD deficiency MAD deficiency (GA II) MCKAT deficiency 2,4-Dienoyl CoA reductase def’ CPT I deficiency CPT II deficiency CACT deficiency Galactokinase def’y Galactoepimerase deficiency Other hemoglobinopathies T cell-related lymphocyte deficiencies Other disorders AMINOACIDOPATHIES ORGANIC ACIDEMIAS FATTY ACID OXIDATION DEFECTS GALACTOSE DISORDERS OTHER METABOLIC DISORDERS RUSP – Secondary Conditions
  • 35.
    35 DC 48 55 60 50 60 55 47 33 49 63 31 48 52 57 32 51 37 30 54 44 32 34 6047 32 55 55 42 31 37 59 47 53 50 66 39 57 60 46 53 58 49 39 36 52 65 62 31 62 50 57 Newborn screening – USA (disorders/groups of disorders) Data from Baby’s First test – www.babysfirsttest.org
  • 36.
    35 DC 48 55 60 50 60 55 47 33 49 63 31 48 52 57 32 51 37 30 54 44 32 34 6047 32 55 55 42 31 37 59 47 53 50 66 39 57 60 46 53 58 49 39 36 52 65 62 31 62 50 57 Newborn screening – USA (disorders/groups of disorders) Estimated patients diagnosed with 25 IEMs on RUSP, 2015-2017 ~1455/year (CDC MMWR 2020;69(36):1265-8) Data from Baby’s First test – www.babysfirsttest.org
  • 37.
    Medical Geneticists • Numberof geneticists per 500,000 people by state
  • 38.
    35 DC 48 55 60 50 60 55 47 33 49 63 31 48 52 57 32 51 37 30 54 44 32 34 6047 32 55 55 42 31 37 59 47 53 50 66 39 57 60 46 53 58 49 39 36 52 65 62 31 62 50 57 Newborn screening – USA (disorders/groups of disorders) Data from Baby’s First test – www.babysfirsttest.org
  • 39.
    35 DC 48 55 60 50 60 55 47 33 49 63 31 48 52 57 32 51 37 30 54 44 32 34 6047 32 55 55 42 31 37 59 47 53 50 66 39 57 60 46 53 58 49 39 36 52 65 62 31 62 50 57 Newborn screening – USA (disorders/groups of disorders) Data from Baby’s First test – www.babysfirsttest.org
  • 40.
    Abnormal NBS Protocol •NBS Lab alerts the PCP office – Repeat specimen – Referral to a specialist • PCP office: – Contacts the family – Facilitates the referral – Interacts with the specialist – roles determined – Supports the family
  • 41.
    Abnormal NBS Protocol •NBS Lab alerts the PCP office – Repeat specimen – Referral to a specialist • PCP office: – Contacts the family – Facilitates the referral – Interacts with the specialist – roles determined – Supports the family • Triages the patient • Initiates testing • Initiates counseling
  • 42.
    Abnormal NBS Protocol •NBS Lab alerts the PCP office – Repeat specimen – Referral to a specialist • PCP office: – Contacts the family – Facilitates the referral – Interacts with the specialist – roles determined – Supports the family • Triages the patient • Initiates testing • Initiates counseling • WITH THE SUPPORT OF A SKILLED CO-PROVIDER
  • 43.
    Triage • Counseling forabnormal newborn screens should always be done ASAP • Management can be: – Emergent – Urgent – Not urgent
  • 44.
    Propionic acidemia Methylmalonic acidemia(mutase) MMA (cobalamin defects) Isovaleric acidemia 3-MCC deficiency HMG CoA lyase deficiency Biotinidase deficiency Holocarboxylase synthetase def’y β-ketothiolase deficiency Glutaric acidemia type I PKU Maple syrup urine disease Homocystinuria Tyrosinemia type I Argininosuccinic aciduria Citrullinemia type I Guanidinoacetate methyltransferase def’y Carnitine update defect MCAD deficiency VLCAD deficiency LCHAD deficiency TFP deficiency Pompe disease Mucopolysaccharidosis type I Mucopolysaccharidosis type II X-linked adrenoleukodystrophy Galactosemia Congenital hypothyroidism Critical congenital cyanotic heart disease Congenital adrenal hyperplasia Cystic fibrosis Hemoglobinopathies Spinal muscular atrophy Severe combined immunodeficiency Hearing loss Other disorders AMINOACIDOPATHIES ORGANIC ACIDEMIAS FATTY ACID OXIDATION DEFECTS GALACTOSE DISORDERS OTHER METABOLIC DISORDERS Triage – Emergent vs Urgent/Non-urgent
  • 45.
    Propionic acidemia Methylmalonic acidemia(mutase) MMA (cobalamin defects) Isovaleric acidemia 3-MCC deficiency HMG CoA lyase deficiency Biotinidase deficiency Holocarboxylase synthetase def’y β-ketothiolase deficiency Glutaric acidemia type I PKU Maple syrup urine disease Homocystinuria Tyrosinemia type I Argininosuccinic aciduria Citrullinemia type I Guanidinoacetate methyltransferase def’y Carnitine update defect MCAD deficiency VLCAD deficiency LCHAD deficiency TFP deficiency Pompe disease Mucopolysaccharidosis type I Mucopolysaccharidosis type II X-linked adrenoleukodystrophy Galactosemia Congenital hypothyroidism Critical congenital cyanotic heart disease Congenital adrenal hyperplasia Cystic fibrosis Hemoglobinopathies Spinal muscular atrophy Severe combined immunodeficiency Hearing loss Other disorders AMINOACIDOPATHIES ORGANIC ACIDEMIAS FATTY ACID OXIDATION DEFECTS GALACTOSE DISORDERS OTHER METABOLIC DISORDERS Triage – Emergent vs Urgent/Non-urgent
  • 46.
    © Copyright 2017Mark Korson, MD. All rights reserved ACMG.net
  • 47.
    © Copyright 2017Mark Korson, MD. All rights reserved ACMG.net © Copyright 2017 Mark Korson, MD. All rights reserved
  • 48.
    © Copyright 2017Mark Korson, MD. All rights reserved ACMG.net © Copyright 2017 Mark Korson, MD. All rights reserved
  • 49.
  • 50.
  • 54.
    An Understanding… • Allemergent disease concerns  referral to a specialist • All non-emergent diseases with unusual concerns  referral to a specialist • A team of skilled co-providers (genetic counselors?) - thoroughly trained and available for PCP assistance and guidance
  • 55.
  • 56.
    Educational Opportunities • Geneticists: –Two-years of training – Combined training with other specialty training – Possibility in the future of loan repayment programs for Genetics and/or Metabolism
  • 57.
    Educational Opportunities • Tobecome a genetic counselor, you must first – earn a minimum of a bachelor's degree: often in the sciences, such as biology, chemistry, molecular biology in psychology or sociology. • Degree Required: Master’s degree Genetic Counseling average of 21 months, study genetics, psychology, counseling and sociology • Certification: Certified Genetic Counselor (CGC) designation by ABGC after passing the board exam which is offered two times a year. • Job Growth (2014-2024): 29%* • Licensure: Many states including Connecticut and Massachusetts have licensure
  • 58.
    Employment in ClinicalSettings • Prenatal and pre-conception – for women and their partners who are pregnant or thinking about becoming pregnant • Pediatric – for children with genetic, or suspected genetic, conditions and their family members • Cancer – for patients with cancer and/or their family members • Cardiovascular – for patients with diseases of the heart or circulatory system and/or their family members • Neurology – for patients with diseases of the brain and nervous system and/or their family members • Assisted reproductive technology / infertility – for couples struggling with fertility or who are carriers of genetic diseases • Psychiatric – for patients living with mental illness and/or their family members
  • 59.
    Employment in Non-clinicalSettings • Research, education, public health settings, and corporate environments. • Examples of roles include: Laboratory – Utilization management, provider and patient support, variant classification, and reporting Research – Coordinating research studies, patient recruitment, data collection and interpretation, manuscript preparation and grant writing Education – Professors, directors of genetic counseling training programs Public health – Newborn screening programs, population screening programs • Non-profit – Patient support and advocacy organizations • Corporate – Dedicated services for employees and their families
  • 60.
    Resources and References •To learn more about genetics/genetic disorders, check out: • New England Regional Genetics Network (www.negenetics.org) • Weitzman Institute/NERGN collaboration (https://www.weitzmaninstitute.org/genetics/)
  • 61.
    • www.nsgc.org/Policy-Research-and-Publications/Genetic-Counselor-Workforce • AmericanCollege of Obstetricians and Gynecologists (2019) Committee Opinion #793: Hereditary Cancer Syndromes and Risk Assessment • Jackson Laboratories Hereditary Cancer Modules • The primary care physician role in cancer genetics: a qualitative study of patient experience Fiona A Miller, June C Carroll, Brenda J Wilson, Jessica P Bytautas, Judith Allanson, Mario Cappelli, Sonya de Laat, Fred Saibil • Family Practice, Volume 27, Issue 5, October 2010, Pages 563– 569, https://doi.org/10.1093/fampra/cmq035 61 Resources and References
  • 62.
    Question #1 There isa shortage of medical geneticists? A. True B. False
  • 63.
    Question #1 There isa shortage of medical geneticists? A. True B. False
  • 64.
    Question #2 There isa shortage of genetic counselors? A. True B. False
  • 65.
    Question #2 There isa shortage of genetic counselors? A. True B. False
  • 66.
    Question #3 A positivenewborn screen for a possible urea cycle disorder requires an emergent referral to a specialist. A. True B. False
  • 67.
    Question #3 A positivenewborn screen for a possible urea cycle disorder requires an emergent referral to a specialist. A. True B. False
  • 68.
    Question #4 A positivenewborn screen for possible x-linked adrenoleukodystrophy requires an emergent referral to a specialist. A. True B. False
  • 69.
    Question #4 A positivenewborn screen for possible x-linked adrenoleukodystrophy requires an emergent referral to a specialist. A. True B. False
  • 70.
    Question #5 A variantof uncertain significance is a pathogenic variant. A. True B. False
  • 71.
    Question #5 A variantof uncertain significance is a pathogenic variant. A. True B. False

Editor's Notes

  • #25 Introduce red flags: Ashklenazi, 1st degree relative under 50 Triple negative ES, PR and HER2 (normal cell growth under the age of 60
  • #26  Details: Autosomal dominant inheritance Affected individuals in every generation Any child of an affected individual has a 50% chance of inheriting the trait; unaffected family members do not pass it to their children Males and females equally likely to be affected (although there may be sex-limited expression, such as with ovarian cancer)
  • #31 Some patients are quite concerned because they want to know do I have a mutation or not Seen in affected and not